Jennison Associates LLC trimmed its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 4.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 19,357 shares of the company’s stock after selling 944 shares during the quarter. Jennison Associates LLC’s holdings in BridgeBio Pharma were worth $781,000 at the end of […]
Moody Aldrich Partners LLC cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 124,984 shares of the company’s stock after selling 12,528 shares during the period. Moody Aldrich Partners LLC’s holdings in BridgeBio Pharma were worth $5,046,000 as of […]
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $29.76, but opened at $30.49. BridgeBio Pharma shares last traded at $30.08, with a volume of 180,372 shares traded. Wall Street Analyst Weigh In Several brokerages have issued reports on BBIO. […]
Raymond James initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research note issued to investors on Thursday, StockNewsAPI reports. The firm issued an outperform rating and a $45.00 price target on the stock. Other analysts have also recently issued reports about the stock. Citigroup lifted their price objective on shares […]
Rhumbline Advisers grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 179,759 shares of the company’s stock after acquiring an additional 1,924 shares during the period. […]